Lucerne, Switzerland (2025)

IEOC Office
Jul 12, 2024
2 min read

Updated: Jul 3

IEOC/an-vision Symposium June 19-21, 2025

The Lucerne, Switzerland Symposium was the largest event ever held by the IEOC. Attendees numbered 131, along with seven exhibitors and seven poster presenters. Trainee presentation awards were given for podium and poster presentations; those will be updated here shortly. New board members were elected, Drs. Silvia Stadler and Catherine Nunnery, and outgoing board members were thanked (Drs. Tim Knott and Claudia Hartley). The Saturday event of boating and dinner on the lake Lucerne beneath the Swiss Alps drew 127 attendees, which put a lovely exclamation mark at the end of the amazing collaborative meeting. More details will be shared on a post-event HTML email to go out shortly, and the link will be posted here. Members may download presentation PPTs slides, course proceedings and notes are complimentary, see below.

Thank you to all who made this event a great success! See you next year in Florida at the WEC.

Symposium Schedule & Proceedings

Speaker PowerPoint Notes

State-of-the-Art Speakers

Dr. Richard J. McMullen Jr., DACVO, DECVO, CAQ Equine Ophthalmology (Germany)

“Infracyanine Green (Emundo®) and Indocyanine Green Photodynamic and Photothermal Therapy in Equine Ophthalmology”

Overview and description of photodynamic (PDT) and photothermal therapy (PTT)
How indo- (ICG) and infracyanine (InfraCG) green-based PDT/PTT found their way into equine ophthalmology
Descriptions and applications of ICG- and InfraCG-based PDT/PTT in equine ophthalmology:
- Corneoscleral squamous cell carcinoma (SCC)
- Eyelid and periocular neoplasia (SCC, sarcoids, melanocytoma)
- Immune mediated keratitis (IMMK)
- Corneal tissue welding
  - Descemet’s membrane ruptures/separation/detachments
  - Surgical incision closure
- Future research

State of the Art Lecturer Sponsored by:

Medical Laser Technology Ltd.

Dr. Simon Pot, DVM, PhD, DACVO, DECVO

"Corneal cross-linking: what's new / what else is new?"

Through its stabilizing effects on the stromal extracellular matrix and its antimicrobial effects, UV-A/Riboflavin crosslinking of the cornea (CXL) is a useful adjunctive therapy for infectious corneal diseases.

Following a short introduction of basic concepts, in this keynote lecture we will:

present the current state of research
cover some clinical disease features that might limit treatment efficacy, and how to overcome those to optimize treatment outcome (in other words: what have we learned during the past five years that is relevant for the use of CXL in our clinic?)
discuss potential new crosslinking strategies, but also different therapeutic strategies altogether.

State of the Art Lecturer Sponsored by:

Medical VET AG

Thank You Sponsors

Thank you to an-vision, Inc./an-vision, GmbH, for agreeing to be our 2025 Namesake Sponsor!